<DOC>
	<DOC>NCT00430898</DOC>
	<brief_summary>The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.</brief_summary>
	<brief_title>Basiliximab in Moderate to Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>In addition to others, Men or women age 1875 Diagnosis of ulcerative colitis confirmed through screening endoscopy. Extent of disease must involve at least the left colon Moderate to severe disease (Mayo Score 612). Systemic features of tachycardia, fever, and/or significant anemia should not be present. Inadequate response despite treatment with prednisone 40 50 mg/day (or other oral steroid at equivalent dose) orally for a minimum of 14 days immediately preceding study entry In addition to other protocoldefined conditions, Pregnancy Stool study that shows presence of ova and parasites, significant bacterial pathogens, or C. difficile toxin Colitis that is indeterminate, suggestive of Crohn's disease, or isolated to the rectum, based on endoscopic and/or biopsy findings Severely ill patients as evidenced by protocoldefined systemic criteria Chest radiograph abnormalities consistent with an infectious process History of colonic dysplasia HIV infection Known viral Hepatitis B or C infection History of or exposure to tuberculosis within 6 months before study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>ulcerative colitis basiliximab</keyword>
</DOC>